In line with these findings, the dual GIP/GLP-1 RA, tirzepatide, was found to delay gastric emptying in T2D, with evidence that this effect may be diminished after 23 days of treatment (ie, suggestive of tachyphylaxis) (Table 2) (117). The gene discussed is GIP; the disease is type 2 diabetes mellitus.